An Open-Label, Two-Period Study to Evaluate the Pharmacokinetics of Lasmiditan in Migraineurs During Acute Migraine Attacks and During Inter-Ictal Periods
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 18 Aug 2017 Planned End Date changed from 16 Mar 2018 to 1 Mar 2018.
- 18 Aug 2017 Planned primary completion date changed from 16 Mar 2018 to 1 Mar 2018.
- 18 Aug 2017 Status changed from not yet recruiting to recruiting.